SEI Investments
KLRS

SEI Investments’s Kalaris Therapeutics KLRS Stock Holding History

SEI Investments’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-856
Closed -$42.4K – 2689
2023
Q3 		$42.4K Hold
856
– – ﹤0.01% 2573
2023
Q2 		$67K Buy
+856
New +$81.4K ﹤0.01% 2598

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

SEI Investments's KLRS Position: Q4 2023 in Review

SEI Investments sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 856 shares — an estimated $42.4K sold.

SEI Investments first reported a position in KLRS in Q2 2023 and held it in 2 quarters. The position peaked at $67K in Q2 2023. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • SEI Investments reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • SEI Investments sold 856 Kalaris Therapeutics shares in Q4 2023, an estimated $42.4K.
  • SEI Investments first reported a position in Kalaris Therapeutics in Q2 2023 and held it in 2 quarters.
  • SEI Investments's Kalaris Therapeutics position peaked at $67K in Q2 2023.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on SEI Investments's 13F filing for Q4 2023, filed 14 Feb 2024.